Syndax Pharmaceuticals (1T3) Financial Statements
Syndax Pharmaceuticals Financial Overview
Syndax Pharmaceuticals's market cap is currently $1.09B. The company's EPS TTM is $-2.52; its P/E ratio is -5.42; Syndax Pharmaceuticals is estimated to report earnings on November 2, 2026, and the estimated EPS forecast is $-0.44. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 172.35M | $ 23.68M | $ 0.00 | $ 0.00 | $ 139.71M |
| Gross Profit | $ 165.38M | $ 22.85M | $ 0.00 | $ 0.00 | $ 139.71M |
| Operating Income | $ -273.08M | $ -339.67M | $ -229.95M | $ -151.76M | $ 26.22M |
| EBITDA | $ -251.63M | $ -313.82M | $ -209.14M | $ -146.17M | $ 26.87M |
| Net Income | $ -285.42M | $ -318.76M | $ -209.36M | $ -149.34M | $ 24.93M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 413.69M | $ 582.91M | $ 577.58M | $ 484.40M | $ 446.83M |
| Total Assets | $ 529.71M | $ 724.82M | $ 612.88M | $ 497.24M | $ 449.66M |
| Total Debt | $ 346.48M | $ 345.74M | $ 1.64M | $ 1.16M | $ 20.97M |
| Net Debt | $ 211.55M | $ 191.66M | $ -293.76M | $ -73.19M | $ -201.00M |
| Total Liabilities | $ 465.08M | $ 436.69M | $ 58.68M | $ 29.79M | $ 41.29M |
| Stockholders' Equity | $ 64.63M | $ 288.12M | $ 554.20M | $ 467.45M | $ 408.37M |
| Cash Flow | |||||
| Free Cash Flow | $ -323.17M | $ -274.90M | $ -160.60M | $ -133.90M | $ 29.00M |
| Operating Cash Flow | $ -322.98M | $ -274.90M | $ -160.60M | $ -133.68M | $ 29.13M |
| Investing Cash Flow | $ 290.04M | $ -219.78M | $ 117.61M | $ -186.19M | $ -40.87M |
| Financing Cash Flow | $ 13.68M | $ 353.37M | $ 264.13M | $ 172.25M | $ 118.46M |
Currency in USD